Scroll down the timeline to trace the history of the pneumococcal Advance Market Commitment, from concept to launch
Scroll down the timeline to trace the history of the pneumococcal Advance Market Commitment, from concept to launch
Cameroon introduces vaccine to combat the prime cause of pneumonia.
The Government of Central African Republic begins introducing pneumococcal vaccine.
Based on SDF v3.0, UNICEF issues a second Call for Supply Offers for the procurement of pneumococcal vaccines under the AMC.
introduction of pneumococcal vaccine in the Democratic Republic of Congo.
Government of Honduras adds pneumococcal vaccine to its national immunisation programme.
Three more countries - Guyan, Sierra Leone, Yemen - introduce pneumococcal vaccine into their routine immunisation programmes.
Kenya marks the global roll out of pneumococcal vaccine against the world's leading cause of child death: pneumococcal vaccines on their way to more than 40 developing countries.
Developing nations begin introducing new vaccine against major killer within a year of its introduction in rich countries: first roll out of pneumococcal vaccines in Latin America.
The GAVI Board approves the grandfathering of the AMC such that all countries that were eligible for GAVI support at the time of signature of the AMC legal agreements – in June 2009 – are still able to access pneumococcal vaccines through GAVI at the AMC terms and conditions.
The first two companies to make long-term commitments to supply new vaccines against pneumococcal disease. GlaxoSmithKline (GSK) and Pfizer Inc. Supply may start as early as 2010 and at a fraction of the price charged in industrialised countries.
The AMC Secretariat announces that four suppliers have made offers to supply vaccines under the pneumococcal AMC.
Panacea Biotect Ltd and the Serum institute of India publicly announce their registration. First call for offers are issued on Friday 4 September 2009.
Based on strategic demand forecast, UNICEF to issue its first call for AMC supply offers this summer.
The Finance Ministers of Italy, the United Kingdom, Canada, Russia, Norway and The Bill & Melinda Gates Foundation together with GAVI Alliance partners World Bank, UNICEF and WHO, formally activated the AMC pilot project against pneumococcal disease.
Donors decided to create an Implementation Working Group (IWG) with the task of recommending a specific proposal for the AMC structure and parameters. Implementation Working Group report recommends terms for the pilot AMC for pneumococcal vaccines.
The Economic Expert Group issues its final report
The AMC Independent Assessment Committee (IAC) meets for the first time to undergo a training session.
The AMC Economic Expert Group meets for the third time to discuss AMC pricing and design issues.
The Target Product Profiles (TPP), endorsed by WHO Strategic Advisory Group of Experts (SAGE) on 6 November 2007, are approved by the WHO Director General. The next step is endorsement by the AMC Independent Assessment Committee (IAC) after which the TPP are considered final and official.
UNICEF makes a written declaration of interest to operate as procurement agent for the AMC.
The Independent Assessment Committee (IAC) selection panel meets for the second occasion and finalises the selection of IAC members according to criteria.
The Independent Assessment Committee (IAC) selection panel meets for the first time to select IAC members according to specific criteria.
The AMC Economic Expert Group meets for the second time to discuss AMC pricing and design issues.
The Target Product Profiles (TPP) expert group meets to consider the draft TPP. Leading up to the meeting, several subgroups worked on specific issues and then came to conclusions on the draft TPP.
The AMC Economic Expert Group meets for the first time to discuss AMC pricing and design issues.
A call for applications for the AMC Independent Assessment Committee (IAC) was issued on the AMC website. This announcement was also made public through specialised websites, relevant newspapers and the GAVI Alliance’s extensive professional contacts.
Canada, Italy, Norway, Russia, the United Kingdom, and The Bill & Melinda Gates Foundation commit US$ 1.5 billion to launch the first AMC to help speed the development and availability of a new vaccine which is expected to save the lives of 5.4 million children by 2030. The new initiative will target pneumoccal disease, a major cause of pneumonia and meningitis that kills 1.6 million people every year.
Hosted by Her Majesty’s Treasury, the Technical Working Group holds its second meeting and reviews the technical, institutional and financial aspects of a pilot AMC for a pneumoccal vaccine.
Hosted by the Italian Treasury, a Technical Working Group composed of representatives from 15 potential donor countries, a range of other institutions (such as the European Committee, the World Bank, the GAVI Alliance, The Bill & Melinda Gates Foundation and WHO) and industry representatives, meet for a first time and review the technical, institutional and financial aspects of a pilot AMC for a pneumococcal vaccine.
An Independent Expert Committee is convened to provide an independent recommendation on which vaccine would be most suitable for the initial AMC pilot. The recommended candidate for the first AMC pilot is pneumcoccal disease. Pneumococcal disease kills around 1.6 million people a year, most of them children. A successful AMC would prevent roughly 5.4 million deaths by 2030.
The Expert Committee also recommend a second AMC for a malaria vaccine be explored to stimulate early research and development investment, and to pilot the impact of the AMC on early stage vaccines. A successful malaria AMC would prevent roughly 2 million deaths by 2030.
G7 Finance Ministers launch a consultation process to advise on technical aspects of a pilot AMC. The World Bank and the GAVI Alliance provide significant assistance on the design of a pilot AMC. An Advisory Group brought together AMC stakeholders, academics and technical experts in the global health community to provide insight into the technical and structural options for the pilot.
A Disease Expert Committee was also convened to provide an independent recommendation on which vaccine would be most suitable for the initial AMC pilot.
The advisory process concluded that AMCs are a feasible, innovative, sustainable, cost-effective, results-oriented and market-based tool in the fight against global disease and poverty.
At the G8 Meeting in London, the Italian Minister of Economy and Finance, Guilio Tremonti, presents the report Background papers to Advanced Market Commitments for Vaccines: A new tool in the fight against disease and poverty.
The Center for Global Development (CGD) publishes the report Making markets for vaccines: Ideas for action, lead authors Michael Kremer, Ruth Levine and Owen Barder. The AMC (originally named “Pull Mechanisms”) working group was a policy research group, convened by the Global Health Policy Research Network at the CGD, to explore the feasibility of advance guarantee agreements as a tool for stimulating research, development and production of vaccines for neglected developing-country diseases. Funding for working group meetings, analytic work and consultations was provided under a grant from The Bill & Melinda Gates Foundation. The CGD continued to work on the AMC idea and published additional papers.